Haemonetics

Cell and Gene Therapy

Antengene | June 28, 2022

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a clinical trial collaboration with BeiGene to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of selinexor in combination with BeiGene's anti-PD-1...

Cell and Gene Therapy

Gritstone bio | December 07, 2021

Gritstone bio, Inc. a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced the expansion of their agreement in order to support the development of a self-amplifying mRNA vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstone’s Omicron vaccine ...

Phanes Therapeutics | June 16, 2020

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Medical

Businesswire | June 29, 2023

Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense. Alloy has exclusively licensed IP underlying the AntiClastic ASO platform from Sudhir Agrawal’s Arnay Sciences LLC. Antisense therapeutics hold promise for reaching many undruggable intrac...